Marksans Pharma Limited has submitted to the Exchange, the Audited financial results for the period ended March 31, 2026.
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 14.7 pts more than Nifty Microcap 250 and 15.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Marksans Pharma reported strong full-year FY2025-26 results with consolidated revenue from operations of Rs 30,334.71 million, up 12.8% year-on-year from Rs 26,891.74 million. Profit after tax grew 9.8% to Rs 4,200.64 million, while total comprehensive income surged 38.5% to Rs 5,962.12 million, boosted by favorable forex gains of Rs 500.95 million. The company expanded its global footprint with two new subsidiaries (Europe and Canada) incorporated in January 2026. The Board recommended a final dividend of Rs 0.90 per share (90%). Statutory auditors MSKA & Associates LLP issued an unmodified (clean) opinion on both standalone and consolidated financial statements.
The company delivered robust profitability growth with PAT up ~10% YoY, driven by operational strength and forex tailwinds. The clean audit opinion and new market expansions signal positive momentum, supporting investor confidence.